Approval · Notice of Compliance 17129 · 2015
SUMATRIPTAN INJECTION, USP: Notice of Compliance 17129
Issued July 24, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17129
- Date
- July 24, 2015
- Company
- Mylan Pharmaceuticals UlcEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- New dosage form, new dosage strength, additional/replacemkent manufacturing site
- Therapeutic class
- 5-ht1 receptor agonist
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUMATRIPTAN INJECTION, USP | 02443953 | Approved |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 6 MG per 0.5ML